One to one hundred nanometer-sized iron oxide particles are known as iron oxide nanoparticles. Their principal forms are magnetite (Fe3O4) and maghemite (-Fe2O3), which is magnetite in an oxidized state. Iron oxide or iron nanoparticles have the potential to be used in cancer magnetic nanotherapy. They are centered on the magnetic spin effect in free radical reactions and semiconductor materials’ ability to produce oxygen free radicals. Furthermore, they can control oxidative stress in biological media exposed to non-uniform electromagnetic radiation.
What Are the Applications of Iron Oxide or Iron Nanoparticles?
Nanoparticles are at the leading edge of nanotechnology’s rapid development. They have unique size-dependent properties that make them indispensable and better than the rest in many human activities. Because of their non-toxic role in biological systems, iron oxide nanoparticles have shown great promise in biomedical applications in recent years. Iron oxide nanoparticles’ magnetic and semiconductor properties may also lead to multifunctional medical applications. These AG nanoparticles have antibacterial, antifungal, and anticancer properties. Iron nanoparticles have been drug-functionalized for cancer treatment and diagnosis.
Iron oxides are compounds found in nature that can be easily synthesized in the laboratory. Iron oxide nanoparticles (NPs) are materials with sizes ranging from 1 to 100 nm that are composed of magnetite (Fe3O4) or maghemite (-Fe2O3). Because of the Néelian and Brownian relaxations, these nanoparticles can disperse in biological fluids while responding to an external magnetic field.
Because of their unique characteristics, such as superparamagnetism, surface-to-volume ratio, larger surface area, and simple separation methodology, iron oxide nanoparticles have received much attention.
How Are Iron Oxide Nanoparticles Created?
Iron oxide nanoparticles were created by precipitating sodium hydroxide and ammonium hydroxide in isobutanol. In the synthesis, isobutanol served as a surfactant. The ceo2 nanoparticles were calcined for 100 minutes to 5 hours at temperatures ranging from 300 to 600°C. Superparamagnetic iron oxide nanoparticles are what they sound like.
SPIONs (superparamagnetic iron oxide nanoparticles) are a multipurpose class of MRI contrast agents. In addition to their ability for magnetic drug targeting, these iron oxide nanoparticles have clinical applications such as identifying hepatocellular carcinomas and as magnetic fluid hyperthermia treatment for cancers. SPIONs are the most extensively researched inorganic nanocarrier systems for drug delivery. These nanocarriers are non-toxic, biodegradable, biocompatible, and rapidly eliminated from the human body via iron metabolism pathways.
Iron Oxide Nanoparticle Synthesis
Many reports have described efficient synthesis approaches to produce shape-controlled, stable, biocompatible, and monodispersed iron oxide NPs over the last few decades. Co-precipitation, hydrothermal synthesis, thermal decomposition, sonochemical synthesis, sonochemical synthetic routes, and microemulsion are all standard methods for producing high-quality iron oxide NPs. Furthermore, these NPs can be produced using other methods such as laser pyrolysis techniques, microorganism or bacterial synthesis (particularly Magnetotactic and iron-reducing bacteria, among others), and electrochemical synthesis.
The author’s bio – SSNANO is committed to providing an extensive and expanding portfolio of magnetic AG nanoparticles to meet any research needs as a supplier of the most comprehensive overview of nanoparticle products with varying sizes and surface properties.
To meet our customers’ diverse needs, we now offer a line of non-magnetic Iron Oxide Nanorods with rod-shaped structures. These iron oxide nanorods are tasteless, non-toxic, insoluble in alkali, and slightly soluble in acid, and can be widely used in coatings, plastics, paints, and pharmaceutical fields.
Apart from that, if you are interested to know about Intervention radiology then visit our World category.
